Skip to main content

Research Repository

See what's under the surface

Advanced Search

Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours

Haque, Farhana; Varlet, Pascale; Puntonet, Julien; Storer, Lisa; Bountali, Aikaterini; Rahman, Ruman; Grill, Jacques; Carcaboso, Angel M.; Jones, Chris; Layfield, Robert; Grundy, Richard G.

Authors

Farhana Haque

Pascale Varlet

Julien Puntonet

Lisa Storer

Aikaterini Bountali

Ruman Rahman ruman.rahman@nottingham.ac.uk

Jacques Grill

Angel M. Carcaboso

Chris Jones

Robert Layfield

Richard G. Grundy



Abstract

Missense somatic mutations affecting histone H3.1 and H3.3 proteins are now accepted as the hallmark of paediatric diffuse intrinsic pontine gliomas (DIPG), non-brain stem paediatric high grade gliomas (pHGG) as well as a subset of adult glioblastoma multiforme (GBM). Different mutations give rise to one of three amino acid substitutions at two critical positions within the histone tails, K27M, G34R/V. Several studies have highlighted gene expression and epigenetic changes associated with histone H3 mutations; however their precise roles in tumourigenesis remain incompletely understood. Determining how such amino acid substitutions in a protein affect its properties can be challenging because of difficulties in detecting and tracking mutant proteins within cells and tissues. Here we describe a strategy for the generation of antibodies to discriminate G34R and G34V mutant histone H3 proteins from their wild-type counterparts. Antibodies were validated by western blotting and immunocytochemistry, using recombinant H3.3 proteins and paediatric GBM cell lines. The H3-G34R antibody demonstrated a high degree of selectivity towards its target sequence. Accordingly, immunostaining on a cohort of 22 formalin-fixed paraffin embedded tumours with a previously known H3.3 G34R mutation status, detected successfully the corresponding mutant protein in 11/11 G34R cases. Since there was a high concordance between genotype and immunohistochemical analysis of G34R mutant tumour samples, we analysed a series of tissue microarrays (TMAs) to assess the specificity of the antibody in a range of paediatric brain tumours, and noted immunoreactivity in 2/634 cases. Importantly, we describe the generation and validation of highly specific antibodies for G34 mutations. Overall our work adds to an extremely valuable portfolio of antibodies, not only for histopathologic detection of tumour-associated mutant histone sequences, but also facilitating the study of spatial/anatomical aspects of tumour formation and the identification of downstream targets and pathways in malignant glioma progression.

Journal Article Type Article
Publication Date Jun 6, 2017
Journal Acta Neuropathologica Communications
Electronic ISSN 2015-5960
Publisher Springer Verlag
Peer Reviewed Peer Reviewed
Volume 5
Article Number e45
Pages 1-9
APA6 Citation Haque, F., Varlet, P., Puntonet, J., Storer, L., Bountali, A., Rahman, R., …Grundy, R. G. (2017). Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours. Acta Neuropathologica Communications, 5, 1-9. https://doi.org/10.1186/s40478-017-0449-1
DOI https://doi.org/10.1186/s40478-017-0449-1
Keywords Histone mutations ; H3 ; 3H3 ; DIPG ; pHGG ; Brain tumour
Publisher URL https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-017-0449-1
Copyright Statement Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0

Files

G34R_antibody_ActaNeuroPathComms_2017.pdf (1.3 Mb)
PDF

Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0





You might also like



Downloadable Citations

;